Renaissance Partners and Aurora Growth Capital Acquire Genetic S.p.A. from CVC as Pavese Family Reinvests

Ampersand Capital Partners Leads $18.5M Growth Investment in Genezen

November 2, 2023

Biotechnology

Genezen closed an $18.5 million follow-on growth equity financing led by Ampersand Capital Partners to accelerate expansion of its viral vector development and GMP manufacturing capabilities. The capital will support build-out and technology investments at Genezen's facilities (including the Fishers, Indiana GMP viral vector site) to scale retroviral, lentiviral and AAV vector production and support additional customer programs.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Aurora Capital Partners Acquires GenServe

August 5, 2024

Industrial Services

Aurora Capital Partners has acquired GenServe, an independent provider of backup power and critical power resiliency services. Aurora intends to deploy growth capital and execute a buy-and-build strategy to expand GenServe’s geographic footprint and service offerings across healthcare, data centers, utilities and other critical infrastructure end markets.

LLR Partners Makes Growth Investment in Genesee Scientific

October 19, 2021

Medical Devices

LLR Partners completed a growth investment in Genesee Scientific, a San Diego–based manufacturer and distributor of life-science consumables and laboratory equipment. The partnership will fund expansion of Genesee's product portfolio and scaling of its national footprint; Audax Private Debt provided unitranche financing to support the transaction.

Novartis Acquires Vedere Bio

September 30, 2020

Biotechnology

Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.